Research Platform Myelofibrosis and Anemia

Recruiting now

Conditions studied: Primary Myelofibrosis, Secondary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Anemia, Myelofibrosis; Anemia, Myelofibrosis

In brief

The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study, a tumor research platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of disease and to collect patient-reported outcomes for patients with primary and secondary myelofibrosis and anemia in Germany.

Key facts

Study ID

NCT06976918

Run by

iOMEDICO AG

People needed

200

Starts

2026-02-19

Expected to finish

2031-09-01

Last updated by the study team

2026-06-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Confirmed diagnosis of primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF) (Note: diagnosis according to WHO-2017, ICC-2022 or WHO-2022 or IWG-MRT criteria, respectively).
• Diagnosis of anemia at the time of enrollment as per individual, clinical assessment by the local physician.
• Start of first or subsequent systemic treatment for MF.
• Informed consent and registration for the GSG-MPN Bioregistry.
• Willingness and capability to participate in PRO assessment.
• Signed and dated informed consent form for RHODOLITE at the latest six weeks after start of the respective systemic MF treatment.

You may not qualify if…

• No systemic therapy for diagnosed primary or secondary MF.
• Planned allogenic stem cell transplantation (allo-SCT) or active participation in an interventional clinical trial.

Where it is running

• Multiple sites all over Germany — Multiple Locations, Germany (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.